Información Nordic Pharma

SOBRE NOSOTROS

Información y Noticias

Nordic Pharma has acquired ALTIM® (cortivazol) pre-filled syringe to strengthen their Rheumatology portfolio
- by marpalop

Paris, January 2022 – Nordic Pharma is pleased to…

Corporativo Nordic Phama

Paris, January 2022 – Nordic Pharma is pleased to announce that they have entered into an agreement with SANOFI to fully acquire the rights to ALTIM® (cortivazol), a legacy product in France.

ALTIM® contains a 3.75mg/1.5ml cortivazol suspension for injection, presented in a pre-filled syringe, and is approved in France in Rheumatology indications, where a local corticosteroid treatment is required. See prescribing information: Résumé des caractéristiques du produit – ALTIM 3,75 mg/1,5 ml, suspension injectable en seringue pré-remplie – Base de données publique des médicaments (medicaments.gouv.fr)

This acquisition supports Nordic Pharma’s strategy to grow its proprietary portfolio and to become a key player in Rheumatology in France and beyond.

ALTIM® was commercialized in France since the 70’s and subsequently withdrawn from the French market by Sanofi in 2018 due to manufacturing issues. It is the intention of Nordic Pharma to re-engineer the process and the manufacturing for both the active substance and the finished product to allow the product to be re-launched onto the French market at the earliest possibility as the product is still requested by clinicians.

Jean-Michel Quinot, CEO of Nordic Pharma stated:” We are very pleased to have reached an agreement with Sanofi allowing us to re-introduce ALTIM® into the French market. Nordic Pharma is dedicated to providing Patients and Physicians with innovative medications addressing significant unmet medical needs. We are very eager to further expand our successful collaboration with Sanofi.”

Veronique Rebours-Mory, CSO of Nordic Pharma stated: “Physicians are still demanding this unique treatment option for Rheumatology patients, and despite the challenge and investment needed, we are committed to solving the manufacturing issues that led to the discontinuation of the product.”

  About Nordic Pharma

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We have established deep roots throughout Europe, and more recently, expanded in North America and Japan, with increased partnerships worldwide.

Nordic Pharma focusses on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women’s Health and Critical Care (Anaesthesiology, Haematology, Oncology).

https://www.nordicpharma.com/   About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. Sanofi prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. Sanofi stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

https://www.sanofi.com/
Positive EMA opinion for the use of Teysuno in metastatic colorectal cancer
- by marpalop

Nordic Pharma has announced that on 16 December…

Corporativo Nordic Phama

Nordic Pharma has announced that on 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion Teysuno: Pending EC decision | European Medicines Agency (europa.eu)] recommending the use of Teysuno (tegafur/gimeracil/oteracil) for the treatment of patients with metastatic colorectal cancer who cannot continue fluoropyrimidine treatment due to specific toxicities: hand-foot syndrome and cardiotoxicity. The CHMP supports including patients who developed these toxicities in the adjuvant setting in addition to metastatic patients.

Teysuno® is an oral fluoropyrimidine with similar efficacy, but improved safety profile compared with other fluoropyrimidines.

Based on this positive opinion Teysuno will be indicated in adults:

  • for the treatment of advanced gastric cancer when given in combination with cisplatin (current indication).
  • as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting (pending European Committee decision).
  New fluoropyrimidine for patients with metastatic colorectal cancer nordic_pharma_thumbnail_green_colon

In metastatic colorectal cancer the typical first-line chemotherapy contains of a fluoropyrimidine used in various combinations.

Jean-Michel Quinot, CEO of Nordic Pharma stated: ”This is important news for patients with metastatic colorectal cancer. Teysuno offers those patients suffering from toxicities that can cause discontinuation of therapy an alternative fluoropyrimidine therapy which allows them to continue systemic treatment that is known to significantly prolong survival. By being able to meet this medical need, we hope to contribute to improving the lives of these patients. We want to particularly thank medical oncologists and patients in different European countries who contributed to collecting crucial clinical data for this new indication.”

Iris van Lakerveld, Global Oncology Lead added: “Fluoropyrimidines are, and will continue to be, the cornerstone of chemotherapy treatment in metastatic colorectal cancer. A significant group of patients can now be offered an alternative, in the event that chemotherapy needs to be delayed, the dose reduced or fully stopped because of hand-foot syndrome or cardiotoxicity. Side effects with chemotherapy are inevitable. With Teysuno, physicians and patients will have an additional therapy when needed, allowing optimal benefit of fluoropyrimidine treatment.

Nordic Pharma has licenced Teysuno® from Taiho Pharmaceutical Co., Ltd. in Japan. In Japan, the product is known as TS-1 and is approved for various solid tumours, including gastric and colorectal cancer. Since 2011 Teysuno has been on the European market in 17 countries. In total, the product is marketed in over 30 countries worldwide.

This positive CHMP opinion is a first step in providing patients with metastatic colorectal cancer access to Teysuno. EMA’s opinion needs to be adopted by the European Commission, and subsequently country-specific reimbursement applications will be done at the level of each Member State to ensure this access.

  About Nordic Pharma

Nordic Pharma is a medium-sized, fully integrated international pharma company.

Nordic Pharma’s focus is on the development and commercialization of specialty products, which include niche hospital and orphan products, to address unmet medical needs. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: rheumatology, women’s health and critical care (anaesthesia, haematology and oncology).

Find out more on www.nordicpharma.com. Contact: oncology@nordicpharma.com

TEY-2022-01-002

European Commission approves Teysuno in metastatic colorectal cancer
- by marpalop

Nordic Pharma announces that on the 24th of…

Corporativo Nordic Phama

Nordic Pharma announces that on the 24th of January, the European Commission (EC) approved the new indication for Teysuno® (tegafur/gimeracil/oteracil) for the treatment of patients with metastatic colorectal cancer who cannot continue fluoropyrimidine treatment due to specific toxicities: hand-foot syndrome and cardiotoxicity.

Nordic Pharma received a positive scientific opinion recommending approval of the use of Teysuno in metastatic colorectal cancer from EMA’s Committee for Medicinal Products for Human Use (CHMP) in December 2021.

Based on this approval, Teysuno will be indicated in adults:
  • for the treatment of advanced gastric cancer when given in combination with cisplatin (current indication).
  • as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting
  New fluoropyrimidine for patients with metastatic colorectal cancer nordic_pharma_thumbnail_green_colon

In metastatic colorectal cancer the typical first-line chemotherapy consists of a fluoropyrimidine used in various combinations.

Teysuno is an oral fluoropyrimidine with similar efficacy, but improved specific safety profile compared with other fluoropyrimidines.

Jean-Michel Quinot, CEO of Nordic Pharma stated: ”This is important news for patients with metastatic colorectal cancer. Teysuno offers those patients suffering from toxicities that can cause discontinuation of therapy an alternative fluoropyrimidine therapy which allows them to continue systemic treatment that is known to significantly prolong survival. By being able to meet this medical need, we hope to contribute to improving the lives of these patients. We want to particularly thank medical oncologists and patients in different European countries who contributed to collecting crucial clinical data for this new indication.”

Iris van Lakerveld, Global Oncology Lead added: “Fluoropyrimidines are, and will continue to be, the cornerstone of chemotherapy treatment in metastatic colorectal cancer. A significant group of patients can now be offered an alternative, in the event that chemotherapy needs to be delayed, the dose reduced or fully stopped because of hand-foot syndrome or cardiotoxicity. Side effects with chemotherapy are inevitable. With Teysuno, physicians and patients will have an additional therapy when needed, allowing optimal benefit of fluoropyrimidine treatment.

Nordic Pharma licences Teysuno from Taiho Pharmaceutical Co., Ltd. in Japan. In Japan, the product is known as TS-1 and is approved for various solid tumours, including gastric and colorectal cancer. Since 2011 Teysuno has been on the European market in 17 countries. In total, the product is marketed in over 30 countries worldwide. The approval of the European Commission is an important step in providing patients with metastatic colorectal cancer access to Teysuno. Subsequently country-specific reimbursement applications will be done at the level of each Member State to ensure this access.

  About Nordic Pharma Nordic Pharma is a medium-sized, fully integrated international pharma company.

Nordic Pharma’s focus is on the development and commercialization of specialty products, which include niche hospital and orphan products, to address unmet medical needs. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: rheumatology, women’s health and critical care (anaesthesia, haematology and oncology).

Find out more on www.nordicpharma.com. Email: oncology@nordicpharma.com

TEY-2022-01-016
Nordic Pharma present at CPhI !
- by marpalop

Nordic Pharma will be attending CPhI Worldwide in Milan, Italy…

Corporativo Nordic Phama
Nordic Pharma will be attending CPhI Worldwide in Milan, Italy from November 9th-11th 2021. We are actively looking for late stage partnering opportunities ideally within our core therapeutic areas of Women’s Health, Rheumatology and Critical Care. If you would like to get in touch and possibly meet us there, please contact busdev@nordicpharma.com   Nordic-Pharma-present-at-CPhI
Nordixate® Methotrexate Pre-filled Syringe approved in Colombia
- by marpalop

Nordic Pharma AAP is pleased to announce that…

Corporativo Nordic Phama
Nordic Pharma AAP is pleased to announce that the Nordixate® Methotrexate Pre-filled Syringe has been issued market authorization by Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or INVIMA, the Colombian National Food and Drug Surveillance Institute. With our local partner, Vitalis Laboratorio, we are working towards a launch early next year. Thank you to everyone who has been involved in achieving this approval. nordic-pharma-vitalis-expertos-en-inyectables
New Headquarters Offices
- by marpalop

Both of Nordic Pharma HQs, located in France…

Corporativo Nordic Phama

Both of Nordic Pharma HQs, located in France and in the Netherlands, have recently moved.

Nordic Pharma HQ NL has relocated to a new office in the Schiphol area as of June 1st, 2021. You will find our new address and phone number below:​​​​​​​

Nordic Pharma B.V. Siriusdreef 41 2132 WT Hoofddorp The Netherlands Phone number: 085 – 48 35 871

Nordic-Pharma-New Headquarters Offices

Nordic Pharma B.V., our Dutch affiliate, is also located here. 

 

Our second HQ in Paris, France, also relocated on March 1st, 2021 to the following address: 

Nordic Pharma 216 Boulevard Saint Germain 75007 Paris, France Phone number: +33 (0)1 70 37 28 02

Nordic-Pharma-New Headquarters-Offices-Paris
Nordimet® PFS and Pen are launched in Chile!
- by marpalop

Nordic Pharma Americas, Asia, Pacific are pleased to…

Corporativo Nordic Phama
Nordic-Pharma-Nordimet-PFS-and-Pen-are-launched-in-Chile

Nordic Pharma Americas, Asia, Pacific are pleased to announce that as of the 15th of April, Nordimet® PFS and Pen are officially launched in Chile via our partner Gador.

This exciting milestone represents the first launch of the Nordic Pharma methotrexate products in Latin America.
Día Internacional de la Mujer
- by marpalop

Desde Nordic Pharma España compartimos nuestra felicitación corporativa…

Nordic Pharma España
Desde Nordic Pharma España compartimos nuestra felicitación corporativa en este #DíaInternacionaldelamujer. Nuestra compañía apuesta por las personas, el talento, el compromiso y la lealtad, no atendiendo a otros parámetros que no sean los marcados entre nuestros valores y nuestra misión. ¡Feliz Día Internacional de la Mujer! #DíadelaMujer
Mes de las Enfermedades Reumáticas
- by marpalop

Desde Nordic Pharma, con gran orgullo, apoyamos la…

Nordic Pharma España
Desde Nordic Pharma, con gran orgullo, apoyamos la campaña de ConArtritis (Coordinadora Nacional de Artritis) durante este mes de octubre, “Mes de las Enfermedades Reumáticas”, con objeto de dar visibilidad a estas patologías y a las personas que las padecen. Por eso hoy en nuestra compañía nos hemos sumado a #VenDeVerdeAR rindiendo así un homenaje a pacientes y a los profesionales que trabajan a diario contra esta enfermedad. #OctAR21 #VenDeVerdeAR  
Re-Certificación” como Great Place To Work®
- by marpalop

Todos los que formamos parte del Equipo de…

Nordic Pharma España
Todos los que formamos parte del Equipo de NORDIC PHARMA España estamos orgullosos de anunciar que hemos conseguido la “Re-Certificación” como Great Place To Work®. Una vez más la credibilidad , el respeto, la imparcialidad, el orgullo y el compañerismo han marcado y “con nota” nuestras respuestas. Esta Re-certificación, sin duda refleja nuestro alto nivel de confianza y satisfacción, y fomenta nuestra cultura de alto rendimiento. ¡¡¡Enhorabuena a todos!!!  
III Día Mundial de la Seguridad del Paciente
- by marpalop

Hoy se celebra el 3er Día Mundial de…

Nordic Pharma España
Hoy se celebra el 3er Día Mundial de la Seguridad del Paciente. El objetivo final de todas y cada una de las entidades que nos dedicamos a la atención sanitaria de un modo u otro es velar por el bienestar del paciente. Desde Nordic Pharma España y Portugal queremos sumarnos a la celebración de este día y mostrar así nuestro firme compromiso con los pacientes y todos aquellos aspectos que redunden en una mejora en su calidad de vida. #DíaMundialSeguridadPaciente
GPTW Certified
- by marpalop

Gracias al trabajo en equipo, obtuvimos la certificación…

Nordic Pharma España
Gracias al trabajo en equipo, obtuvimos la certificación #GPTWcertified. Hoy queremos celebrarlo con nuestros colaboradores y con toda la comunidad de empresas que ponen en el centro a las personas. ¡Feliz Día Internacional de la Certificación!  
Innovación incremental
- by marpalop

Compartimos hoy interesante artículo sobre el último evento…

Noticias destacadas
Compartimos hoy interesante artículo sobre el último evento organizado por la Fundación Bamberg el pasado lunes. Durante el mismo, Jorge Vázquez, vocal Nacional de Farmacéuticos de Industria del Consejo General de Farmacéuticos, impartió una conferencia sobre la #InnovaciónIncremental. "Cuando las personas enfermamos, nos olvidamos del coste y buscamos el mejor tratamiento". Una de las variables más primordiales es la calidad de vida de los pacientes. Hay grandes retos, como la atención al paciente, que éste pase de agudo a crónico; el de la provisión de servicios sanitarios; el de la Administración Reguladora pagadora; el de los profesionales de salud y el de los productos farmacéuticos, que nos lleva a buscar nueva innovación. En la última década, aproximadamente el 40% de los fármacos que han llegado al mercado lo han hecho a través de la innovación incremental... Noticia completa: https://lnkd.in/diKP3thq
Artritis idiopática juvenil
- by marpalop

La artritis idiopática juvenil es la patología reumática…

Noticias destacadas
La artritis idiopática juvenil es la patología reumática más frecuente en la infancia, una de las enfermedades crónicas más prevalentes en niños y una importante causa de morbilidad infantil. La Sociedad Española de Reumatología (SER) ofrece una completa información sobre esta patología en su página web que puede resultar de utilidad para aquellos padres cuyos hijos acaba de recibir este diagnóstico. Accede a esta información aquí: https://lnkd.in/dSVUDB4 #ArtritisIdiopática #Reumatología
ConArtritis
- by marpalop

Hoy queremos compartir uno de los videos que…

Noticias destacadas
Hoy queremos compartir uno de los videos que ha retomado recientemente ConArtritis (Coordinadora Nacional de Artritis), en el que podemos comprobar claramente, que las limitaciones que produce esta patología, no son imaginables. Los trabajadores de la redacción del periódico El País se pusieron en la piel de las personas con Artritis y pudieron experimentar lo que sentirían en su puesto de trabajo si padeciesen esta enfermedad crónica y autoinmune.
Podcast SER
- by marpalop

¿Conoces los podcast de la American College of…

Noticias destacadas
¿Conoces los podcast de la American College of Rheumatology? Este nuevo canal ofrece píldoras informativas en formato descargable que permite estar al tanto de las novedades en torno al abordaje de las patologías reumáticas. Con una periodicidad mensual, ofrecen información relativa las últimas investigaciones, casos prácticos, abordajes innovadores, novedades en tratamientos, etcétera. Tienen formato de entrevista y participan en ellos prestigiosos reumatólogos a nivel internacional.       Puedes descargarlos aquí: https://lnkd.in/dJFZ4UWa #Reumatología
Estudio “Periodontitis as a Risk Factor for Rheumatoid Arthritis”
- by marpalop

La periodontitis se asocia con un mayor riesgo…

Noticias destacadas
La periodontitis se asocia con un mayor riesgo de desarrollar Artritis Reumatoide, según un estudio publicado en la revista Scientific Research Report. Para la realización del estudio, titulado "Periodontitis as a Risk Factor for Rheumatoid Arthritis: a Matched-Cohort Study", se analizaron 17 años de historias clínicas de 691.506 pacientes. Si deseas más infomación: https://lnkd.in/dnWCq57r #Reumatología #ArtritisReumatoide #Periodontitis
Diagnóstico AR
- by marpalop

¿Han diagnosticado a tu hijo con Artritis Reumatoide?…

Noticias destacadas
¿Han diagnosticado a tu hijo con Artritis Reumatoide? La Sociedad Española de Reumatología dispone en su página web de un decálogo para padres de hijos con Artritis Reumatoide en el que comparte los 10 pasos básicos que han de tenerse en cuenta a la hora de tratar a estos pacientes. Pueden consultar esta información en: https://lnkd.in/dMqdkajc #Niños #ArtritisReumatoide
Diccionario de la Sociedad Americana de Reumatología
- by marpalop

Hay más de 100 enfermedades reumatológicas diferentes. La…

Noticias destacadas
Hay más de 100 enfermedades reumatológicas diferentes. La Sociedad Americana de Reumatología dispone en su página web de un “diccionario” (en inglés y español) en el que puede consultarse información sobre cada una de ellas. El paciente encontrará una descripción de la enfermedad, qué es, qué la causa, cómo tratarla y algunos consejos de hábitos de vida saludables que, puestos en práctica, contribuyen a convivir mejor con estas patologías. También puede ser una herramienta útil para el profesional sanitario. Muchos pacientes olvidan preguntar en la consulta aquellas cuestiones que les preocupan o bien, acaban de recibir el diagnóstico y necesitan algo de tiempo e información adicional para asumirlo. El diccionario puede consultarse aquí: https://lnkd.in/duUdrf_q #Reumatología #ArtritisReumatoide
Segunda vida para los fármacos
- by marpalop

La investigación y los avances en tecnología ofrecen…

Noticias destacadas
La investigación y los avances en tecnología ofrecen hoy por hoy un desarrollo de los fármacos más eficaz y eficiente. Probar mediante un cribado automático la posible efectividad de un abanico de compuestos para una determinada patología es, hoy por hoy, una realidad. Nos hacemos eco de la publicaciónde Farmaindustria con interesante artículo en el que se expone cómo la pandemia ha acelerado este proceso de reposicionamiento farmacológico y cómo el big data o los avances en estrategia computacional han contribuido a hacer posible que “viejos fármacos” tengan nuevos usos.

Áreas terapéuticas